Morgan Stanley analyst Judah Frommer has maintained their bullish stance on PTCT stock, giving a Buy rating on April 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer has given his Buy rating due to a combination of factors surrounding PTC Therapeutics’ recent developments. A key element is the positive opinion issued by the CHMP for Sephience (sepiapterin) as a treatment for PKU, which covers all ages and severities of the disease. This broad label recognition highlights the drug’s potential impact, as demonstrated in the APHENITY study.
With the European Commission’s ratification expected soon, PTC Therapeutics is well-positioned to capitalize on a significant commercial opportunity. The company is targeting a global PKU patient population of 58,000, with a substantial portion in the US lacking effective treatment options. Launch preparations are focused on Germany and other key EU markets, and the upcoming PDUFA date for the US submission further supports the anticipated market penetration. These strategic moves underpin Frommer’s positive outlook on the stock.
PTCT’s price has also changed moderately for the past six months – from $40.750 to $49.530, which is a 21.55% increase.